scholarly journals The relationship between KRAS gene mutations and HLA class I antigen downregulation in the metastasis of non-small cell lung cancer

2013 ◽  
Vol 41 (5) ◽  
pp. 1473-1483 ◽  
Author(s):  
Xiao-Peng He ◽  
Fu-Jie Song ◽  
Xiang-Yan Liu ◽  
Zhou Wang ◽  
Xiang-Xin Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Gene Mutations ◽  
Hla Class I ◽  
Small Cell ◽  
Small Cell Lung ◽  
Kras Gene ◽  
Hla Class I Antigen ◽  
The Relationship

scholarly journals HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer

2007 ◽  
Vol 98 (9) ◽  
pp. 1424-1430 ◽  
Author(s):  
Eiki Kikuchi ◽  
Koichi Yamazaki ◽  
Toshihiko Torigoe ◽  
Yasushi Cho ◽  
Masaki Miyamoto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Hla Class I ◽  
Antigen Expression ◽  
Small Cell ◽  
Small Cell Lung ◽  
Favorable Prognosis ◽  
Hla Class I Antigen

scholarly journals Synergistic Occurrence of EGFR, ALK, and KRAS Gene Mutations in a Patient with Non-small Cell Lung Cancer (Adenocarcinoma)

2019 ◽  
Vol 71 ◽  
pp. 45-48
Author(s):  
Dinesh Chandra Doval ◽  
Rupal Tripathi ◽  
Kumardeep Dutta Choudhury ◽  
Ajay Sharma ◽  
Ullas Batra ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Care Center ◽  
Gene Mutations ◽  
Small Cell ◽  
North India ◽  
Small Cell Lung ◽  
Standard Chemotherapy ◽  
Kras Gene

Lung cancer is a commonly diagnosed malignancy. Adenocarcinoma, a subgroup of non-small cell lung cancer, is the commonest form and presents in an advanced stage of the disease, leaving a limited treatment option. Response to the standard chemotherapy regimens is overall poor. We present a case of synergistic occurrence of triple gene mutations in a patient with well-diff erentiated adenocarcinoma lung treated at a tertiary cancer care center in North India.

scholarly journals Racial and Ethnic Differences in the Relationship between Aspirin Use and Non–Small Cell Lung Cancer Risk and Survival

2018 ◽  
Vol 27 (12) ◽  
pp. 1518-1526 ◽  
Author(s):  
Patricia Erickson ◽  
Lisa D. Gardner ◽  
Christopher A. Loffredo ◽  
Diane Marie St. George ◽  
Elise D. Bowman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Risk ◽  
Small Cell Lung Cancer ◽  
Ethnic Differences ◽  
Cell Lung Cancer ◽  
Lung Cancer Risk ◽  
Small Cell ◽  
Small Cell Lung ◽  
Racial And Ethnic Differences ◽  
The Relationship

Cigarette Smoke-Induced Reduction of 14-3-3σ Expression Promotes The Progression of Non-Small Cell Lung Cancer

2021 ◽  
Author(s):  
Longxia Dai ◽  
Quanwen Deng ◽  
Aibin Liu ◽  
Shuya He ◽  
Qiong Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Protein Expression ◽  
Small Cell Lung Cancer ◽  
Cigarette Smoke ◽  
Cell Lung Cancer ◽  
A549 Cells ◽  
Small Cell ◽  
Small Cell Lung ◽  
Smoking Group ◽  
The Relationship

Abstract Background Lung cancer is a common malignant tumour and the leading cause of cancer death. Smoking is closely related to lung cancer, which can not only induce the occurrence of lung cancer but also affect its progress and prognosis. Objectives To investigated the relationship between smoking and 14-3-3σ protein expression in non-small-cell lung cancer (NSCLC), investigated the relationship between 14-3-3σ expression and cell migration in A549 cells induced by cigarette smoke extract (CSE) and explored whether DNA methylation plays a role in the decreased expression of 14-3-3σ induced by CSE. Methods 14-3-3σ protein expression was examined by immunohistochemistry in 152 NSCLC tissue samples. In vitro experiments were divided into three groups: The current smoking group (CS), the ex-smoking group (ES) and the normal control group (NC). Cell transfection was used for 14-3-3σ protein overexpression. The mRNA and protein expression levels of 14-3-3σ were detected by RT-PCR and Western blotting, respectively. Cell migration was detected by Transwell and wound-healing assays, and the methylation of 14-3-3σ was detected by methylation-specific PCR. Results 14-3-3σ protein expression was decreased in NSCLC patients with a history of smoking. The expression of 14-3-3σ was decreased in A549 cells treated with CSE. The migration capacity of A549 cells treated with CSE was enhanced. DNA methylation in the cigarette smoke-treated A549 cells was higher than that in the untreated cells. Conclusion Cigarette smoke induced reduction of 14-3-3σ expression can promote the progression of non-small cell lung cancer.

Comparison of molecular signatures in small cell lung cancer with or without homologous recombination associated gene mutations.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e20580-e20580
Author(s):  
Lili Fu ◽  
Feifei Li ◽  
Dandan Ren ◽  
Beibei Mao ◽  
Huan Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Homologous Recombination ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Checkpoint Inhibitors ◽  
Gene Mutations ◽  
Small Cell ◽  
Small Cell Lung ◽  
Homologous Recombination Deficiency

e20580 Background: Small cell lung cancer (SCLC) is an aggressive neuroendocrine subtype of lung cancer with high mortality. Recently, Immune checkpoint inhibitors (ICIs) have been shown to have the potential to improve the prognosis of SCLC, but little is known about immunotherapeutic biomarkers. Homologous recombination deficiency (HRD) is demonstrated to be a response predictor to immunotherapies in gynecologic cancers, while limited studies were reported in small cell lung cancer. Herein, we analyze the mutational pattern of HRR related genes in a Chinese SCLC cohort and further analyze the relationship between HRR-gene mutations and tumor mutational burden. Methods: Target gene sequencing (543 genes) was performed in 133 Genecast cohort with small cell lung cancer. PD-L1 expression were evaluated for 90 among 133 patients using the SP142 PD-L1 immunohistochemistry assay. Results: Among 133 patients, 47 (35.3%) had HRR-gene mutations. ATM (8.3%), NBN (4.5%) and BRCA2 (4.5%) were the top 3 mutated HRR-gene in the cohort，followed by ATR (3.8%), BARD1 (3.8%), BRCA1 (3.8%), PALB2 (3.8%), RAD50 (3.8%), CHEK2 (3.0%), BLM (3.0%), BRIP1(2.3%), CHEK1(1.5%), RAD52(1.5%), and MRE11A (0.8%). Pathogenic somatic and germline mutations of HRR genes were identified in 11 (11/47, 23.4%) and 3 (3/47, 6.4%) patients, respectively. 1 (1/47, 2.1%) patient carried both germline and somatic variants. Genomic landscape revealed that TP53 and RB1 were commonly mutated genes in SCLC cohort. Mutations in KMT2D, AR and RTK-RAS pathway occurred more frequently in the HRR-Mut group, compared with the wildtype ones. Furthermore, we found that mutations in HRR-gene were associated with high TMB (Wilcoxon, p = 0.048), and patients with high TMB (≥median) showed a higher proportion of positive PD-L1 expression in 90 SCLC patients. Conclusions: Our data indicated that genomic alterations associated with HRR-genes have a positive correlation with high TMB, and detection of HRR-gene mutation status probably could help identify patients who might benefit from immune checkpoint blockade therapy. Keywords: Small cell lung cancer, Homologous recombination deficiency, Immunotherapy.

Sign in / Sign up

Export Citation Format

Share Document